HR Execs on the Move

Clinuvel

www.clinuvel.com

 
Clinuvel is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

WEX Pharmaceuticals

WEX Pharmaceuticals Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Validation Inc

Validation Inc is a Whitehall, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health & Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.

International Stem Cell Corporation

International Stem Cell Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.